145 related articles for article (PubMed ID: 29668449)
1. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria.
Iskrov GG; Jakovljevic MM; Stefanov RS
Folia Med (Plovdiv); 2018 Mar; 60(1):79-91. PubMed ID: 29668449
[TBL] [Abstract][Full Text] [Related]
2. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
[TBL] [Abstract][Full Text] [Related]
3. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Schlander M; Dintsios CM; Gandjour A
Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Household and Health Care System Expenditures in Bulgaria.
Mitkova Z; Petrova G
Front Public Health; 2021; 9():675277. PubMed ID: 34277542
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
7. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
8. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
9. Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai.
Cai X; Yang H; Genchev GZ; Lu H; Yu G
Orphanet J Rare Dis; 2019 Oct; 14(1):233. PubMed ID: 31640704
[TBL] [Abstract][Full Text] [Related]
10. Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria.
Mitkova Z; Dimitrova M; Doneva M; Tachkov K; Kamusheva M; Marinov L; Gerasimov N; Tcharaktchiev D; Petrova G
Front Public Health; 2022; 10():1011928. PubMed ID: 36438231
[TBL] [Abstract][Full Text] [Related]
11. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.
Xin XX; Guan XD; Shi LW
Orphanet J Rare Dis; 2016 Jun; 11(1):74. PubMed ID: 27266878
[TBL] [Abstract][Full Text] [Related]
12. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
13. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
14. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
15. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
Schlander M; Beck M
Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
[TBL] [Abstract][Full Text] [Related]
16. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
17. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
18. Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China.
Xin XX; Zhao L; Guan XD; Shi LW
Chin Med J (Engl); 2016 Jun; 129(12):1387-93. PubMed ID: 27270531
[TBL] [Abstract][Full Text] [Related]
19. Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research Database.
Hsu JC; Wu HC; Feng WC; Chou CH; Lai EC; Lu CY
PLoS One; 2018; 13(9):e0204206. PubMed ID: 30240449
[TBL] [Abstract][Full Text] [Related]
20. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
